Patients will undergo a standard EBUS examination, with sampling using a standard 22G EBUS needle.

Patients will undergo a standard EBUS examination, with sampling using an Acquire TBNB needle.

Mediastinal Lymphadenopathy

Mediastinal and hilar lymph node sampling using a standard 22G EBUS needle

EBUS-TBNA

Mediastinal and hilar lymph node sampling using the Acquire TBNB needle

Acquire TBNB

Royal Brompton Hospital

EBUS-TBNA vs Acquire TBNB

Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) Versus the Endobronchial Ultrasound Transbronchial Needle Biopsy Using the Acquire Needle in the Assessment of Mediastinal and Hilar Lymphadenopathy: a Randomised Trial

Royal Brompton & Harefield NHS Foundation Trust

Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days).

Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days).
Sorafenib: Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.

Sorafenib

Sex: Female, Male

Region of Enrollment

Determination of absolute lymphocyte count (ALC), lymphadenopathy, splenomegaly, and/or marrow leukemia as measured by 4-color flow minimal residual disease (MRD) panel after 3 cycles of study treatment. (Decrease in absolute lymphocyte count by 50%, decrease in lymphadenopathy (sum of lymph node product) by 50%, decrease in splenomegaly by 50%, or decrease in leukemia infiltration of the bone marrow by 50%.)

Overall Response Rate

A response assessment must be performed 2 months following completion of therapy to document responses, including a bone marrow if in clinical response (CR) and a computed tomography (or magnetic resonance imaging scan [MRI]) if initial imaging was abnormal or physical examination inconclusive.

To Determine the iwCLL-WG Defined Overall Response Rate (ORR) - Complete Response (CR) and Partial Responses (PR) to 3 Cycles of Sorafenib Therapy and Following the Completion of All Therapy.

Frequency, severity and relatedness of adverse events

Safety and Tolerability

Overall Study

Thomas Kipps, MD

Chronic Lymphocytic Leukemia

Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.

lymphadenopathy/tyrosine

EBUS-TBNA vs Acquire TBNB

Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)

The most complete medicinal herbs database backed by science